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Abstract
Chronic wounds are those wounds which are refractory to treatment, often taking
years to heal. These wounds are complex and may present with elevated protease levels,
resulting in rapid degradation of growth factors, both native and augmented via treatment.
This study’s focus was the development of a system to protect growth factors from
protease mediated degradation.
The protective system consisted of chimeric fusion proteins developed to contain
both a growth factor or known protease inhibitory peptide and an Elastin-Like-Peptide
(ELP)component. The unique phase transitioning abilities of the ELP component allowed
for the self-assembly of these chimeric fusion proteins into a heterogenous nanoparticle
which puts the inhibitory component near the growth factor.
These developed heterogenous nanoparticles showed success in protecting and
preserving the growth factor in highly proteolytic environments as well as in human
chronic wound fluid. Treatment with these nanoparticles in a protease augmented diabetic
mouse model were found to result in enhanced collagen remodeling and resolution of
inflammation.
This system is novel as it places the protease inhibitor in close proximity to the
growth factor, allowing for inhibition of proteases in the immediate environment
surrounding the growth factor. In addition, this system is highly modular, allowing for the
protection of multiple growth factors using the same inhibitor, without having to alter the
amino acid sequences of each individual growth factor.

v

Our results suggest that the developed protective system holds tremendous
promise and potential in the field of wound healing therapy and may help bridge the
translation of growth factor therapies to the clinic. In addition, the modular nature of this
nanoparticular system allows for the opportunity to customize protective systems across
several fields in research and medicine.

vi

Chapter 1: Background1
The impact of chronic wounds on public health is overwhelming, with nearly 2.5
million patients presenting with chronic wounds per year in the USA alone 1. The greatest
impact of these wounds is seen those patients recovering from spinal cord injuries, as
well as in the elderly population1. Of the 12 million people who suffer from diabetes
mellitus here in the USA, roughly 1/3 will present with a foot ulcer at some point in their
life2. These kinds of wounds are particularly dangerous as they commonly become
infected, as well as suffering from other complications which make them refractory to
treatment.
One method for treating chronic wounds is the application of bioactive proteins and
factors, which endeavor to remedy irregular and dysfunctional cellular pathways
commonly found in chronic wounds3-8. One such bioactive protein is the clinically
approved Platelet Derived Growth Factor (PDGF). PDGF treatment (becaplemin;
Regranex gel)9 influences wound healing by inducing both fibroblast proliferation and
migration10. However, despite the promise of this treatment, the clinical success of this
exogenous PDGF therapy has been modest11, requiring multiple reapplications over long
periods of time12.
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One of the biggest barriers to successful treatment and resolution of chronic
wounds is the highly inflammatory environment common in these types of wounds.
Studies have shown that chronic wounds display prolonged periods of inflammation,
combined with elevated protease levels13. These elevated protease levels include
neutrophil derived serine proteases, among them Human Neutrophil Elastase (HNE),
Proteinase-3, Cathepsin-G, and Urokinase plasminogen activator(µPA)14. An additional
class of protease commonly found in the chronic wound environment are Matrix
Metalloproteinases (MMPs)14.
Several studies have described elevated protease levels being found in the chronic
wound environment15. In comparisons between acute and chronic wounds, both
elastases and MMPs were found at elevated levels in wound fluid collected from chronic
wounds13. For example, MMP9 has been found at high levels in chronic wounds such as
diabetic foot ulcers, pressure ulcers, and venous leg ulcers, with 14 fold16, 10-25 fold17,
and 7 fold18 higher MMP9 levels respectively than normal levels of MMP9. Proteases
themselves play a vital part in both angiogenesis and matrix remodeling, both essential
processes for normal wound healing19 Conversely, elevated proteases levels like those
seen in chronic wounds can lead to impaired wound healing19. Indeed, recent data has
shown a direct correlation between a non-healing chronic wounds and elevated protease
levels20,21.
While the protease environment of a chronic wound is diverse, MMPs have seen
the greatest interest from the academic community20. While elevated MMP levels are
indeed a common and serious complication in chronic wounds, recent studies have
suggested that neutrophil derived serine proteases such as HNE also have a potent effect
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on the healing on chronic wounds20. Indeed, the presence of serine proteases such as
HNE and proteinases-3 have been found to enhance inflammation via the recruitment
and activation of neutrophils22. Studies have shown that long periods of persistent
elevated protease levels can result in the degradation of essential wound healing
components, such as the extracellular components fibronectin and collagen , as well as
growth factors and their associated receptors19. The result of such degradation is
impaired and/or blocked wound healing processes19. Studies have shown that chronic
wound fluid with elevated protease levels correlate with the degradation of peptide growth
factors and a reduced population of protease inhibitors23,24. Consequently, advanced
healing modalities, including the application of growth factors, stem cells, and other
protein centered treatments, are likely to suffer potent degradation due to the highly
proteolytic environment of chronic wounds. This degradation could potently affect any
potential treatment, even to the point of rendering them completely ineffective. Therefore,
it is logical to suppose that any attempt at developing a successful growth factor therapy
would require a component to protect the growth factor from proteolytic degradation in
the chronic wound environment. To this end, our lab has developed a system to protect
the growth factor from protease mediated degradation.
This system had numerous requirements to incorporate into its design.
Requirements of this system included a growth factor component relevant to the chronic
wound environment and a protease inhibitory component to protect the growth factor from
protease mediated degradation. These components needed to be successfully
transported/delivered to the wound site. These components also needed to be
nonimmunogenic to prevent unnecessary immunological interactions, and biodegradable
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to allow for reabsorption and avoid excess debris in the wound site. This system was
designed to be heterogenous in order to place the inhibitory components close enough
to the growth factors to allow for proper protection from proteases mediated degradation.
Additionally, the system needed to be stable at biological pH and temperature, allowing
for it to be tested in a rodent model for efficacy and safety.
This system consists of a novel nanoparticulate delivery system, utilizing ElastinLike-Peptides(ELPs) for the delivery of bioactive proteins to the wound 25. This
nanoparticle consists of chimeric fusion proteins composed of the bioactive protein to be
delivered to the wound site, and the Elastin-Like-Peptides(ELPs). ELPs are, as the name
suggests, composed of a sequence motif derived from the hydrophobic domain of
tropoelastin26, a soluble precursor of elastin. Specifically, ELPs are biodegradable and
non-immunogenic polymers composed of the tandemly-repeated blocks of (Val-Pro-GlyX-Gly)N. As a result of this composition, ELPs have a unique property, that being the
ability to self-aggregate into nanoparticles at physiological temperature. ELPs are soluble
in aqueous solutions at temperatures below that of their lower critical solution temperature
(LCST). At temperatures above this LCST, the ELP undergoes a temperature induced
and entropically driven self-assembly into nanoparticles. This transition into a
nanoparticle renders the protein insoluble, resulting in a precipitate. Following expression
in bacteria, this temperature dependent behavior allows these recombinant ELPs to be
rapidly and efficiently purified to through inverse temperature cycling (ITC)27.
Furthermore, our lab has shown that the ELP and growth factor components of the
chimeric fusion proteins maintain both their inhibitory bioactivity and phase transition
properties28-30. These chimeric fusion proteins were found to be beneficial to wound
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healing when the heterogenous nanoparticle treatment was applied to wounds
augmented with proteases in a diabetic mouse wound model.
In this work, we describe a protective system composed of a novel nanoparticulate
protease resistant growth factor formulation for the treatment of highly proteolytic chronic
wounds. These nanoparticles are composed of two chimeric fusion proteins, containing
an ELP component and either PDGF or a known HNE inhibitory peptide. These two fusion
proteins aggregate at physiological temperature, resulting in the formation of
heterogenous nanoparticles due to the unique phase transitioning properties of the ELP.
We also developed several other potentially beneficial growth factor formulations for use
in the treatment of chronic wounds, and which also might be prone to protease
degradation, including KGF, EGF, and VEGF. These were developed in order to test the
efficiency of the HNE inhibitor on multiple growth factors intrinsic to the wound healing
process.
When incubated in the presence of elevated HNE levels, these nanoparticles were
successful in significantly extending the half-life of the growth factor, in both solutions
containing purified HNE, as well as in collected human chronic wound fluid. Furthermore,
treatment with these nanoparticles in a protease supplemented diabetic mouse wound
model resulted in enhanced collagen remodeling and resolution of inflammation. Overall,
our results suggest that this protective nanoparticular system holds immense promise in
the translation of chronic wound healing therapies to clinic.

5

Chapter 2: Characterization of Human Chronic Wound Fluid2
2.1 Introduction
Having seen the limited success of existing therapies for the treatment of chronic
wounds, the main question that presented was simple: What is happening in the wound
that is negating these attempts at treatment? The easiest way to answer that was to
develop a methodology to collect, test, and analyze fluid taken from human chronic
wounds, in order to determine what possible degradative effects are taking place, and
ultimately determine how to address them.
2.2 Materials and Methods
2.2.1 Chronic Wound Fluid Collection
Acquiring chronic wound fluid from patients was the crucial first step in determining
and understanding the bioactivity in the human chronic wound environment. Using a
protocol approved by the Care New England-Kent Hospital Institutional review board,
wound fluid was collected from chronic 11 wound patients at Kent Hospital. Due to the
nature and availability of samples, a power analysis was not utilized for the patient chronic
wound fluid samples. This fluid was collected utilizing PBS wetted filter papers (described
previously18) and shipped on dry ice to Tampa for analysis. These samples were then
stored at -800C for further use. Inclusion criteria included: age ≥18 and age ≤ 80, able to
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give informed consent, and one of the following: open wound >4 weeks on lower leg with
signs/symptoms of chronic venous insufficiency or stage 3 or 4 pressure ulcer, present >
4 weeks. Exclusion criteria included: clinical signs of infection, current treatment with
topical enzymatic debriding agents, and current hyperbaric oxygen therapy.
2.2.2 Growth Factor Degradation Studies
The next step was to ascertain the presence of any agents potentially degradative
to PDGF in the collected chronic would fluid samples. The frozen filter paper samples
were submerged in 150ul of assay buffer (100 mM HEPES, 500mM NaCl, 0.05 % Tween20) in order to elute out proteins from the wound fluid. The chronic wound fluid samples
were then incubated at 370C with PDGF (1mg/ml ) for a total volume 50 μl. 6ul of the
incubated samples were saved/collected at specified time points and stored at -200C for
further use. A Western Blot was then used to visualize the PDGF remaining at the various
time points using the saved samples. A loading control was utilized in the first column to
act as the “0 hours” time, which consisted of only growth factor and assay buffer. The
PDGF degradation was tracked over time using an antibody specific to PDGF (Peprotech
500-P45, 0.2ug/ml dilution used for blotting).
2.2.3 Kinetic Analysis of Protease Activity
The chronic wound fluid samples containing the eluted proteins were then assayed
for HNE activity using the colorimetric drug discovery kit specific to HNE (Enzo
LifeSciences, Catalogue # BML-AK497-0001) as per the manufacture’s recommendation.
The kit consists of a colorimetric substrate specific to HNE (MeOSuc-AAPV-pNA), the
hydrolysis of which increases absorbance at 405nm, allowing for the plotting of substrate
cleavage and degradation over time. This plot of the increased absorbance over time
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generates a slope of the curve that is directly related the level of enzyme activity. Standard
solutions containing predetermined concentrations of purified HNE were used to generate
additional curves and allowed for calculation of standardized slopes. These “control”
slope values were then used to estimate the HNE activity of the wound fluid. The
remaining wound fluid was stored at -800C for further use.
2.2.4 Growth Factor Degradation Studies at Biological Protease Levels
The degradative potential of the protease activity found in the human chronic
wound fluid was determined by incubating PDGF-ELP with biological levels of HNE(HNE
levels similar those found in the human chronic wound fluid previously). These biological
levels of HNE (concentration of 250 μU/μl) were incubated at 37 0C with PDGF-ELP
(1mg/ml in PBS) for total volume 50 μl. 6ul of the incubated samples were saved/collected
at specified time points and stored at -200C for further use. A Western Blot was then used
to visualize the PDGF remaining at the various time points using the collected samples.
The PDGF degradation was tracked over time using an antibody specific to PDGF
(Peprotech 500-P45, 0.2ug/ml dilution used for blotting).
2.3 Results
2.3.1 Rapid Degradation of Biological Peptides in Human Chronic Wound Fluid
Following the incubation of PDGF-ELP in the collected human chronic wound fluid,
a clear pattern of degradation was observed. Many samples showed substantial
degradation overall, with the residual PDGF recovered at various time points showed
potent degradation over the 24hr incubation period. Select samples showed complete
degradation in less than 2 hours (Figure 1A-1B).
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2.3.2 Elevated Protease Activity in Chronic Wound Fluid Correlates to Rapid Growth
Factor Degradation
Elevated HNE activity in chronic wounds have been noted in several studies, with
elevated levels correlating with a wound’s increased probability of being non-healing20.
To determine whether HNE was to blame for the potent and rapid degradation of PDGF
seen when incubated in the human chronic wound fluid samples, a substrate-based assay
was used to establish elevated HNE levels, in triplicate using patient chronic wound
samples. We found that 7 out of the 11 patients presented with elevated HNE activity. Six
of the eleven patients had HNE levels consistent with at least a 65% chance of a wound
being non-healing, according to a comparison/diagnostic chart from Serena and co, while
three of the eleven patients had levels consistent with a 90% chance of a wound being
non-healing20. Those samples with higher HNE levels were the same samples that most
potently degraded the growth factor (Figure 1C).
2.4 Discussion
The majority of human chronic wound fluid samples showed growth factor
degradation in less than 24 hours, with select samples showing complete degradation in
as little as 30 minutes. This contradicts previous analysis conducted on wound fluid, which
reported little, if any degradation of PDGF when incubated in human chronic wound fluid
for 12 hours

32-33.

Then again, the study in question used concentrations of the growth

factor 100 time greater than that used in our study32-33. The study noted that this high
growth factor concentration may have overpowered the protease activity found in the
wound site32-33. In addition, this study does not note any attempt at either identifying or
quantifying the protease activity of the wound fluid, suggesting the possibility that the
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chronic wound fluid used for analysis may have had low levels of proteases. Regardless
of this previous study, we saw a clear correlation between high levels of HNE and PDGF
degradation. In fact, when purified HNE was incubated with PDGF, at levels comparable
to those found in the human chronic wound fluid samples, we observed potent and rapid
growth factor degradation. Indeed, elevated HNE levels have been reported to eliminate
PDGF bioactivity24. With these high levels of HNE being found in a subset of the wound
fluid samples tested, it should be noted that there is a known correlation between elevated
HNE levels and the probability of a wound being non-healing20. The varied clinical
performance of PDGF therapies may be explained by the rapid PDGF degradation seen
when incubated in chronic wound fluid containing elevated HNE levels34. While a possible
solution to this issue would be to simply increase the growth factor concentration to
counteract elevated protease activity33, this may not be optimal, as growth factors
generally have an optimal concentration for bioactivity35. Instead, a system to protect the
growth factor, and its resultant bioactivity, from elevated protease activity would be more
efficient and economical. This system would also need to be stable and functional at both
biological temperature (37° C) and biological pH (pH levels from ~6.95-8).
Both the relatively small sample size of patient wound fluid provided by out
collaborator Dr. Lisa Gould (n=11), as well as the great variability in protease
concentrations found in the patient wound data, should be noted, as both of these
components have relevance to overall conclusions. Specifically, the variability is
addressed later in this work.
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Figure 1: Rapid Degradation of the Growth Factor in Chronic Wound Fluid. (A) Collected
chronic wound fluid samples were incubated with PDGF, with samples taken at various
time points, and visualized via western blot. Results showed complete degradation of
growth factor within 2 hours as shown in this example western blot. (B) The residual
remaining PDGF was quantified using ImageJ for the various time points for each
patient and normalized to PDGF levels at time t=0, and plotted over time. (C) The
wound fluid was then tested for Human Neutrophil Elastase (HNE) activity using
substrate assays, with the results compared to the remaining residual percent of PDGF
remaining showing a correlation between elevated HNE levels and growth factor
degradation. Type of ulcers is indicated by (PU) for Pressure ulcers and (VLU) for
Venous Leg Ulcers.
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Chapter 3: Development and Characterization of Protease Resistant Fusion
Proteins3
3.1 Introduction
Having determined the presence of elevated HNE levels degradative to growth
factors in the human chronic wound fluid samples collected, the next step was to develop
a system to protect these growth factors. This protective system would need to protect
the growth factor long enough to allow for the desired bioactivity to take place, at low
enough concentration to avoid potentially adverse biological reactions. The solution was
the development of a protective system consisting of a protease resistant nanoparticle.
These nanoparticles are comprised of novel fusion proteins that together assemble into
a nanoparticle that places the growth factor in close proximity to the inhibitor, due to the
ELP component. This nanoparticle and its individual fusion protein components were
tested to confirm individual and combined bioactivity, before being tested in both
controlled and biological elevated protease levels to determine efficacy and extent of
growth factor preservation.

3
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3.2 Materials and Methods
3.2.1 Synthesis of Expression Plasmids Containing Genes Encoding Growth Factors and
the Protease Inhibitor PMPD2-ELP
Genes encoding human recombinant PDGF-BB (Accession number NP_002599,
amino

acids

82-190)

and

the

HNE

inhibitory

PMPD2

peptide

(EEKCTPGQVKQQDCNTCTCTPTGVWGCTLMGCQPA)31 were individually cloned in
frame

with

the

gene

encoding

Elastin-Like-Peptide

(ELP,[(VPGVG)2-VPGLG-

(VPGVG)2]10-DYKDDDDK) at the N-terminus within the PUC19 plasmid, to form two new
novel DNA fragments. Using the restriction enzymes Pflm1 and Bgl1 the new novel fusion
DNA fragment, coding for either PMPD2-ELP or PDGF-ELP, was excised from the
PUC19 vector and cloned into a pET25B+ vector modified to include a Sfi1 site as
described previously29. This methodology was repeated to develop the additional growth
factor fusion proteins: EGF-ELP, KGF-ELP, and VEGF-ELP, the sequences of which
were confirmed following insertion into the expression plasmid29.
3.2.2 Expression and Purification of Fusion Proteins
Following the expression of the pET25B+ vector containing the developed fusion
proteins in BLR-D cells, the bacteria were inoculated in 75 ml Terrific Broth (TB) medium
overnight (TB:4ml glycerol, 12.6g potassium dibasic, 2.4g potassium monobasic, 24g
tryptone,12g yeast, all sourced from Thermofisher, in 1 Liter DI water). After 16-18 hours
of incubation and agitation, the 75ml samples was transferred to 1 liter of TB, and the
cells were allowed to culture and incubate overnight. The following day, following 20-22
hours of incubation and agitation, the bacteria were pelleted and harvested using a
centrifuge (3000g, 10 minutes).
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Following pelleting, the cells were resuspended in PBS and sonicated in order to
lyse the cells and release the proteins (12 min total with cycles of 30 sec on and 30 sec
off). This lysed product was then pelleted to remove cellular debris, before being purified
via Inverse Temperature Cycling (ITC), described previously25. PMPD2-ELP and PDGFELP were induced to transition to their self-assembled nanoparticular state through the
addition of 1M NaCl and 3M NaCl respectively, as well as being warmed to 420C (protein
stability preserved to at least 45°C). The proteins were sufficiently purified following 3
rounds of ITC, with the purity confirmed via Western Blots and total protein gels. The
proteins were then resuspended in DI water (pH 7.4) before undergoing dialysis overnight
in order to remove contaminants and extraneous salt. Following dialysis, the proteins
were then lyophilized and stored at room temperature for future use.
The bacterial lysate and purified PDGF and PMPD2 fusion proteins were run on a
polyacrylamide gel and stained with simply safe blue stain for total protein. The
corresponding gel was then subjected to western blot with monoclonal anti-Flag
antibodies (tags the ELP L10-flag, nonspecific to the bioactive component) to confirm the
proteins’ identity.
3.2.3 Confirmation of Protease Resistant Activity
An assay similar to the kinetic assay used previously to characterize HNE activity
was utilized to test for the protease resistant activity of the PMPD2-ELP protein. A control
with a known HNE concentration was used to compare against samples containing the
inhibitor at different concentrations. This allowed for a calculation of relative percent
inhibition between the control and the solutions containing the inhibitor. In addition, the
ELP alone was tested to determine whether ELP exhibits any natural inhibitory activity.

14

3.2.4 Growth Factor Degradation Studies with Nanoparticle Formulations
To determine the bioactivity of the novel protective system, the nanoparticles
(consisting of both a growth factor and the inhibitory component) underwent a degradative
experiment, wherein a 2:1 ratio by weight solution of PMPD2-ELP and growth factor-ELP
was created in PBS . Purified HNE (250 μU/μl) was added to the nanoparticle solution for
a total volume of 50ul, and the solution was incubated at 37 0C. A control consisting of
only the relevant growth factor and the HNE in PBS was incubated simultaneously to use
for comparison. 6ul of the incubated samples were saved/collected at specified time
points and stored at -200C for further use. A Western Blot was then used to visualize the
growth factor remaining at the various time points using the collected samples. The
growth factor degradation was tracked over time using an antibody specific to to the
corresponding growth factor: PDGF (Peprotech 500-P45, 0.2ug/ml dilution used for
blotting), EGF (Peprotech, 500-P45, 1ug/ml dilution used for blotting), KGF (Peprotech
500-P19, 1ug/ml dilution was used for blotting), VEGF (Novus NBP2-596, dilution 2ug/ml
used for Western Blotting).
3.2.5 Growth Factor Degradation Studies with Nanoparticle Formulations in Biological
Environments
The next step involved assessing whether the protective system was functional in
protecting the growth factor in the biological environment of the collected human chronic
wound fluid. For this process, instead of creating a 2:1 ratio of PDGF-ELP and PMPD2ELP in PBS, the ratio was suspended in 50ul of the collected chronic wound fluid samples,
with the rest of the particulars being the same. The control was given the same treatment
with PDGF-ELP(1mg/ml) being incubated in 50 ul of the human chronic wound fluid. The
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collected samples, still 6ul taken a specified time points, were then tested via western blot
alongside a positive control to track the degradation of the growth factor over time. The
blot membranes were exposed, and the resultant Western Blot image was then used to
quantify the relative percentage remaining of the protected vs unprotected growth factor
at the final time point. This percentage remaining was calculated utilizing ImageJ by
comparing the pixel density for the samples at each time point, with thicker darker
pixelated lines correlating with higher concentration of PDGF remaining. These resulting
differences between the original time point and the specified time points that followed
were calculated and conveyed as percentages remaining and the percentage of
increased recovery.
3.3 Results
3.3.1 Successful Creation and Purification of HNE Inhibiting Fusion Protein PMPD2-ELP
and PDGF-ELP
The potent growth factor degradation previously seen due to elevated levels of
HNE indicated the need for system to protect growth factors from protease -mediated
degradation. To create such as system, we developed novel fusion proteins containing
either a formerly investigated powerful HNE inhibiting peptide PMPD231 or PDGF, and an
ELP, to create PMPD2-ELP and PDGF-ELP fusion proteins. These proteins were
successfully expressed in E-Coli and purified(Figure 2A-2B). Additional Growth
Factor(GF)-ELPs were also successfully developed and purified, including EGF-ELP,
VEGF-ELP, and KGF-ELP.
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3.3.2 Nanoparticle Formulation Degradation Test and Kinetic Activity Characteristics
Following purification of the fusion protein PMPD2-ELP, the protein was incubated
with HNE to ascertain if the protein was susceptible to protease-mediated degradation by
HNE. This same process was conducted on the developed PDGF-ELP molecule.
PMPD2-ELP showed no significant degradation, while PDGF-ELP showed the expected
potent and rapid degradation seen previously. The inhibitory bioactivity of the PMPD2ELP fusion protein was then determined by utilizing the kinetic assay previously used to
characterize the protease activity of the human chronic wound fluid. PMPD2-ELP was
found to block the degradative activity of HNE at concentrations of 0.5, 1, and 2 mg/ml.
In addition, it was found that the ELP showed no inhibitory effect on HNE activity(Figure
3) .
3.3.3 Nanoparticle Formulation Protect Growth Factors from Protease Degradation
The inclusion of the ELP element in the fusion proteins allowed for the formation
of heterogenous nanoparticles (NPs) consisting of PMPD2-ELP and a growth factor
(Figure 4A). When compared to nanoparticles consisting of PDGF alone, the
heterogenous nanoparticle containing PMPD2-ELP and PDGF-ELP protected PDGF
from HNE mediated degradation when both groups were prepared and incubated in
controlled buffered solution containing biologically similar levels of HNE(250 uU/ul).
Additional NPs consisting of PMPD2-ELP and either EGF-ELP, VEGF-ELP, or KGF-ELP
were all found to protect the respective growth factor from degradation due to HNE (Figure
4A-4E).
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3.3.4 Heterogenous NPs Formed from PMPD2-ELP and GF-ELP Protect Growth Factors
from HNE Mediated Degradation
Further testing into the abilities of the protective heterogenous nanoparticle system
consisting of PMPD2-ELP and PDGF-ELP was conducting in the collected patient chronic
wound fluid. The heterogenous NP was incubated in the collected patient wound fluid and
samples taken at various time points used in a western blot. PMPD2-ELP was found to
preserve between 20-60% more growth factor on average compared to unprotected
samples. The greatest improvements in growth actor preservation were found in those
samples with HNE levels between 60-250 µU/ µL (Figure 4F-G).
3.4 Discussion
Both fusion proteins were successfully expressed and purified, with each
individually showing the anticipated results when incubated with biological levels of HNE.
PDGF-ELP was found to degrade down to its ELP component, while PMPD2-ELP
withstood HNE degradation. The PMPD2-ELP fusion protein also proved to be bioactive,
with a protein concentration of .5mg/ml in the kinetic assay resulting in complete HNE
inhibition. The combination of these results empathized the promise and potential of using
the combination of both proteins to improve growth factor preservation in the biologically
relevant HNE levels tested.
This developed protective system, involving the creation of growth factor
formulation resistant to HNE degradation, differs from previously attempted methods of
creating protease resistant growth factors36-38. Methods previously attempted have
included the creation of growth factor mutants though the deletion of protease cleavage
sites36-38. While these methods have merit, they tend to have limited applicability,
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requiring a new mutant for each individual growth factor in order to prevent proteolytic
cleavage. In addition, the new mutants are often cumbersome, both in development and
in resultant protein size.
This contrasts with our developed method as this protective system can utilize a
single fusion protein to shield multiple growth factors from protease mediated
degradation. Indeed, our study shows that the protective system was successful at
protecting a total of four growth factors from HNE degradation using the same fusion
protein, PMPD2-ELP. In addition to this benefit, the self-assembly of these nanoparticles
allows for the growth factors to be in close proximity to the HNE inhibitory component,
PMPD2. This approach differs from simply combining the growth factors and inhibitors
as the ELPs ability to self-assembles results in the co-localization of the protease
inhibitors close to the growth factors, resulting in the neutralization of proteases that are
an immediate threat to the relevant growth factor.
Intriguingly, while the nanoparticles were generally successful at improving growth
factor preservation, in certain human chronic wound fluid samples, the nanoparticles had
little to no effect. While this could be due to wound type(such as type of ulcer), or the
duration of the ulcer has, research has found multiple degradative agents in the chronic
wound site. This suggests the possibility of such additional degradative agents in the
collected chronic wound fluid, such as additional proteases, including proteinases and
Matrix Metalloproteases(MMPS).
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That being said, the very nature of the modular design of this nanoparticle
protective system allows for the modification and inclusion of multiple protease inhibitors
to allow for protection of a growth factor from multiple proteases. In this way, strategies
for treatments can be customized according to the specific protease profile of the patient
and wound in question.

Figure 2: Expression and Purification of Chimeric Fusion Peptides. PDGF and PMPD2
were cloned in front of the Elastin like peptide L10-flag, in the cloning vector PUC19 using
PflM1 and BglI sites. (A) The bacterial lysate and purified PDGF and PMPD2 fusion
proteins were run on a polyacrylamide gel and stained with simply safe blue stain for total
protein. (B) The corresponding gel was then subjected to western blot with monoclonal
anti-Flag antibodies (tags the ELP L10-flag) to confirm the proteins’ identity.
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Figure 3: PMPD2-ELP Inhibits Recombinant Human Neutrophil Elastase (HNE). (A)
PMPD2-ELP was incubated with HNE (total concentration 250 uU/ul) for 2, 4 and 24
hours. The samples were then subjected to western blot using anti-flag antibodies to
check for degradation of PMPD2-ELP. (B) The inhibitory efficiency of the PMPD2-ELP
fusion protein was then tested via substrate assay and found to block protease activity at
concentrations as low as 0.5mg/ml.

Figure 4: Heterogeneous Nanoparticle Protects Growth Factors from Protease Mediated
Degradation. (A) Formation of heterogeneous nanoparticle using chimeric fusion proteins
comprising of different functional domains (grey or black). (B-E) Growth factor alone or
heterogeneous NPs containing growth factor and protease inhibitor were incubated with
HNE (250 μU/µl) at the indicated times. Growth factor degradation was visualized using
western blots using antibodies specific to the respective growth factor under study. We
tested (B) PDGF, (C) EGF, (D) KGF and (E) VEGF. (F) PDGF-ELP or Heterogeneous
NPs comprising of PDGF-ELP and PMPD2-ELP were incubated with chronic wound fluid
at the indicated times and protein degradation was quantified using western blots. This
experiment was done using the wound fluid from 11 patients and an example western
blot is shown. (G) The overall percent increase in residual PDGF at 24 hours was
quantified for all patients (n=11) by taking a ratio of remaining PDGF detected at 24 hours
with PMPD2-ELP and without PMPD2-ELP.
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Chapter 4: Efficacy and Safety Testing of Nanoparticles in a Wound Model4
4.1 Introduction
Having seen the success in the controlled in vitro experiments, the next logical
step was to incorporate an animal model. This presented a unique challenge as previous
new data from our lab had shown that mice do not present with elevated protease levels
when wounded. In order to create a suitable test environment for an animal study,
adjustments had to be made. A homozygous diabetic mouse was selected for the animal
model due to their delayed healing characteristics. Additionally, the most common
hospitalized chronic wounds are diabetic ulcers. To address the lack of a high protease
environment, the animal model would need to be supplemented topically with proteases
following wounding. The wounds would then be assessed for wound healing parameters,
including inflammation, re-epithelization, and collagen deposition/distribution.
4.2 Materials and Methods
4.2.1 Application in Animal Model
Altogether 30 genetically diabetic female mice were ordered from The Jackson
Laboratory( Bar Harbar, ME, code: B6.BKS(D)-Leprdb/J). These mice were divided in to
the following treatment groups: HNE alone(n=7), PMPD2+HNE(n=7), ELP+HNE(n=4),
Recombinant

PDGF+HNE

(n=4),

PMPD2-ELP+PDGF-ELP+HNE

(n=4),

and

4
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HNE+PDGF-ELP( n=4). Each mouse was housed in an individual enclosure and between
the ages of 7-9 weeks. The standards put forth by the Committee on Laboratory
Resources, National Institutes of health, in addition to committee of Research Integrity
and Compliance Institutional Animal Care and Use of the University of South Florida, were
used to dictate the care of the animals. During the study, both before and after the
procedure, all animals had free access to both food and water.
4.2.2 Surgical Procedures for Wounding
Vaporized iso flurane (2 to 2.5%, Iso Flo, Abbot Laboratories, North Chicago, Il)
was used to anesthetize the mouse subjects. Using sterile technique and under sterile
conditions, following complete dorsal depilation, a single full-thickness excisional square
wound (1cm by 1cm) was made on the upper back of each mouse using sharp surgical
scissors. Following wounding, a fibrin gel was augmented with HNE(250 uU/ul) for a total
volume of 100ul, and immediately applied to the wound, and continued for a week (2
treatments/week). The aim of this period of HNE supplementation was to create an
elevated protease environment. Following the week of the HNE supplemented gel
treatment, the test groups were treated accordingly. These groups were treated with
either HNE(250uU/ul), HNE(250uU/ul)+ELP (2mg/ml), HNE (250uU/ul)+rPDGF(1mg/ml),
HNE(250uU/ul)+PMPD2-ELP+PDGF-ELP(2mg/ml and 1mg/ml), HNE(250uU/ul)+PDGFELP(2mg/ml), or HNE(250uU/ul)+PMPD2-ELP (2mg/ml), all of which were suspended in
a fibrin gel and used to treat the mice for two weeks (2 treatments/week). These wounds
were dressed using a Tegaderm (3M Health Care, St Paul, MN) bandage measuring
2.5cm by 2.5cm . Note: Recombinant PDGF group was treated 3 times a week in order
to ensure adequate PDGF was applied, similar to previous PDGF studies.
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4.2.3 Preparation of Fibrin Gels
The fibrin gel used to treat the wounds consisted of mixing two separate
components. One component contained the fibrinogen (6.25 mg/ml, Sigma, St Louis,
MO), as well as the supplemental HNE and the respective protein treatment. The other
component consisted of thrombin (12.5 U/ml, Sigma), as well as CaCl(12.5 mmol/L,
Sigma), and 1X tris buffered saline. 80ul of the fibrinogen component was combined with
20ul of the thrombin fraction, and then immediately applied topically to the wound site.
Following gelation (in < 2 minutes), the wound was bandaged with a semi-permeable
polymer-based bandage (ex. Tegaderm™).
4.2.4 Histological Evaluation of Tissues
21 days post wounding, the mice were sacrificed using CO2, followed by a cervical
dislocation to guarantee subject death. The subject wound sites were then collected and
bisected using sharp surgical scissors. Following collection, the samples were then
preserved in either 4% paraformaldehyde or formalin. The formalin preserved samples
were cut and mounted on slides for later staining for 72 hours. Paraformaldehyde
preserved samples were then transferred to a 15% sucrose and 30% sucrose in that order
for 12-24 hours each. Then these tissue samples were preserved in OCT and stored at 200C. The frozen tissue samples were then cut and mounted on slides.
The frozen mounted samples cut from the paraformaldehyde preserved samples
were used for immunofluorescent staining of CD45. First the sections were blocked in
goat serum for 1 hr, before being washed with PBS 3 times for 5 minutes each. Then the
alex fluor 594 (Invitrogen, 1/200 dilution in goat serum) conjugated secondary antibody
was applied to the frozen sections and allowed to incubate at room temperature for 1

24

hour. Following incubation, the samples were again washed in 1xPBS 3 times for 5
minutes each. The stained samples were mounted using DAPI containing mounting
medium (ProLong Diamond Antifade Mountant, P36966, Invitrogen). Cells indicated to be
inflammatory by the tagging of CD45 on the exterior of the cell membrane were quantified
via a cell count of the inflammatory cells of three random microscopic fields per wound
sample (n=22). These samples were then normalized to and compared to control group
(samples treated with HNE alone, no nanoparticle treatment) for ease of comparison
between all groups. The value for the control group was normed to one in figures. To
mitigate experimenter bias, the cell counts were conducted blindly, i.e. The samples were
randomized so the counter did not know what sample it was.
Those mounted samples previously preserved in formalin were then stained with
Hematoxylin and Eosin. These samples were used to measure the wound gap length for
reepithelization analysis using ImageJ. The freehand tool of ImageJ was used to measure
the distance between the edges of the wound site on images taken of the wound sites
(n=30), with the length being measured three separate times and the values averaged.
To mitigate experimenter bias, the wound gap length measurements were conducted
blindly, i.e. The samples were randomized so the experimenter did not know what sample
it was.
In addition to being stained with Hematoxylin and Eosin, those samples preserved
in formalin were also stained with Mason’s Trichrome Stain. This stain was using in
conjunction with ImageJ to quantify the matured collagen present in each of the wound
sites by selecting for and isolating the blue stain of the collagen inherent to the trichrome
stain, in a representative image of each of the wound site samples. These images include

25

the whole of the wound site, allowing ImageJ to determine the area of the image
containing the correct blue wavelength of the collagen, with this area being compared to
the area for the whole image to determine an overall percentage. This overall percentage
of the total field was found three separate times and the values averaged. To mitigate
experimenter bias, the total percentages were conducted blindly, i.e. the samples were
randomized so the experimenter did not know what sample it was.
4.2.5 Statistical Analysis
The Excel Analysis ToolPak was used for statistical analysis, with which we
conducted an Anova and a p-analysis to determine statistical significance, with statistical
significance being defined as p ≤ 0.05. A Power analysis was conducted for in vivo
experiments.
4.3 Results
4.3.1 PMPD2-ELP Significantly Reduces Inflammation in vivo
We determined the efficacy of the heterogenous nanoparticle, consisting of
PMPD2-ELP and PDGF-ELP, and its individual components(PMPD2-ELP, ELP, PDGFELP, etc) in vivo utilizing an animal model modified for chronic wounds presenting with
elevated protease levels. Wound healing product testing most often utilizes a LEPR knock
diabetic mouse, due to its delayed wound healing behavior. This model, however, does
not present an elevated protease environment like that found in chronic wound fluid. Thus,
we supplemented the wounds with purified HNE immediately following wounding and for
the first 7 days prior to treatment with the various proteins. HNE was found to induce
sustained inflammation for the entirety of the study. Large concentrations of leukocyte
cells were found in those samples treated with HNE alone and HNE+PDGF-ELP. This
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inflammation consisting of leukocyte cells was located below, even with, and above the
epidermal level, both within and surrounding the wound. This concentration suggests
considerable inflammation. Those samples treated with PMPD2-ELP showed significantly
fewer leukocytes suggesting much reduced inflammation, while the ELP alone and
PDGF-ELP presented with limited reduction in inflammation (Figure 5A).
4.3.2 PMPD2-ELP Improves Healing of Full Thickness Wounds and Collagen Deposition
Wound closure was quantified using ImageJ to determine the degree to which
each group was successful at reepithelization. The experimental group which presented
with the largest wound gap was the HNE group. Close behind, both the HNE+ELP and
the HNE+recombinant PDGF showed a significant wound gap. Both the HNE+PDGFELP and the HNE+PMPD2-ELP+PDFG-ELP group showed some relative improvement
of the HNE group. The group with the smallest wound gap was that of the HNE+PMPD2ELP group, of which 75% of the subjects showed complete or nearly complete
reepithelization (Figure 5B).
The collagen deposition of the wound site samples was also quantified using
ImageJ, which selected for and assessed the percentage of the wound which showed the
correct “blueness”. The groups which presented with the highest level of collagen
deposition were HNE+PMPD2-ELP and HNE+PMPD2-ELP+PDGF-ELP, followed by the
HNE+ELP.

An

observation

of

interest

was

that

the

HNE+PDGF-ELP

and

HNE+recombinant PDGF groups both showed similar collagen deposition levels to that
of the HNE control group. This could potentially be due to the PDGF degradation by the
HNE prior to the desired positive benefits of the growth factor taking place(Figure 5C).
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4.4 Discussion
Results of treatment with the protective heterogenous nanoparticle system were
overwhelmingly positive, with full thickness wounds created in the diabetic mice
responding to the treatment with improved reepithelization, general resolution of
inflammation, and improvements in collagen deposition and remodeling. The wounds in
question were augmented with elevated levels of purified HNE in an effort to create the
elevated protease environment found in the human chronic wound fluid. This was
necessary as diabetic mice do not present with an elevated protease environment when
wounded. The augment of proteases to these wounds of course does not recreate the
whole of a chronic wound in terms of biochemistry or physiology-instead the aim of this
augmentation was to create an environment that allowed us to show the success of our
nanoparticle in an HNE rich environment similar to that found in the human chronic wound
fluid.
Intriguingly, we found that those wounds treated with HNE+PMPD2-ELP+PDGFELP, HNE+PMPD2-ELP and HNE-ELP alone presented with both significant collagen
production and maturation, as well as significant general granulation of the wound in this
augmented mouse model. This suggests that the ELP components of our nanoparticle
might have a beneficial effect on dermal fibroblasts proliferation, which would agree with
previous works which showed fibroblast proliferation due to ELP treatment 25, 39. Similarly,
those wounds treated with HNE+recombinant PDGF(rPDGF) and HNE+PDGF-ELP
showed similar granulation and collagen deposition to that of the control HNE only group,
which suggests that the presence of HNE in the wound site result in PDGF having limited
efficacy.
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Additionally, these samples showed quite elevated inflammation. Conversely, the
group treated with HNE+PMPD2-ELP showed the least overall inflammation as well as a
remodeled wound site, both in terms of collagen deposition and reepithelization.

Figure 5: PMPD2-ELP Reduced Inflammation, Improved Collagen, and Reduced
Wound Gap. (5A) Inflammation was measured using a cell count of stained lymphocyte
cells. (5B) Re-epithelization was determined by examining the wound gap.(5C) Collagen
deposition/maturation was evaluated using Masons’ Trichrome Stain. Overall, the group
treated with PMPD2-ELP alone showed the greatest improvement in wound gap
closure, inflammation reduction, and collagen maturation and deposition. An Anova test
was conducted to determine statistical significance, with those samples with statistical
significance indicated by the star symbol, with P values of 0.05 or less.
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Chapter 5: Development of Multi-Protease Resistant Nanoparticles5
5.1 Introduction
Having seen the success of the HNE inhibitory heterogeneous nanoparticle at
improving growth factor preservation, the next logical step was improving the efficiency
of the inhibitory component. While the nanoparticle was successful overall, the greatest
improvement was seen in those samples containing protease levels between 60250uU/ul. Those samples with the highest protease levels showed slim improvement in
growth factor preservation, with significant degradation within 2 hours. This necessitated
development of a more efficient HNE inhibitor. New novel fusion proteins were developed
to include an additional HNE inhibitor, Secretary Leukocyte Peptidase Inhibitor (SLPI), as
well as combination of SLPI and PMPD2. The purpose of developing these proteins was
to determine if alternative HNE inhibitors could be more efficient. SLPI is a well-known
HNE inhibitor naturally found in humans, making an optimal option for potential use in
human chronic wounds40. Additional proteins were developed to contain either multiple
copies of the PMPD2 peptide (specifically (PMPD2)5) or a combination of both SLPI and
PMPD2. These proteins were developed to determine if either multiple copies of PMPD2
or combination of both PMPD2 and SLPI could work in synergy to improve upon the HNE
inhibitory activity of PMPD2-ELP, to improve upon overall growth factor preservation.

5
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Those samples with the lowest protease levels also showed surprising
degradation, with growth factor degradation occurring at around 24 hours. The possibility
in these cases is that there are additional proteases in the wound site contributing to
growth factor degradation. To address this issue, the human chronic would fluid samples
was

tested

and

found

to

present

with

elevated

levels

of

MMPs

(Matrix

Metalloproteinases), specifically MMP2 and MMP9. MMPs are proteases naturally found
in the human chronic wound environment, with essential roles in tissue remodeling and
repair41. Similar to HNE, the human body has a natural system for additional protease
stimulation and inhibition, a system which may result in upcycling and potential damage
to the wound site. Chronic wounds have been known to present with elevated protease
levels, specifically of MMP2 and MMP920,42. The elevated levels seen in the human
chronic wound fluid tested suggested that additional inhibitory fusion proteins specific to
MMP2 and MMP9 activity might be necessary for improved treatment of chronic wounds.
The ideal inhibitory component for fusion with an ELP would need to be relatively short in
terms of base pairs, as longer peptide sequences could disrupt the ELPs ability to selfassemble at body temperature28-30. APP (Amyloid Precursor Protein) and STX are both
peptides that are small enough to not interfere with ELP activity, as well as both peptides
having been successfully synthesized and found to have inhibitory activity specific to
MMP2 and MMP9 respectively43.
5.2 Materials and Methods
5.2.1 Kinetic Analysis of Protease Activity
The first step was to determine if there any additional agent/s degradative to PDGF
in the human chronic wound fluid. For analysis and quantification of MMP2/MMP9 activity
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in the wound fluid, the reconstituted human chronic wound fluid was assayed for MMP2
and MMP9 activity using colorimetric drug discovery kits for MMP2 and MMP9 (Enzo
LifeSciences, Catalogue # BML-AK408-0001 and Enzo LifeSciences, Catalogue # BMLAK410-0001) as per the manufacturer’s recommendations. This kit contains a highly
specific colorimetric substrate for MMP2 and MMP9 (Ac-Pro-Leu-Gly-[2-mercapto-4methyl-pentanoyl]-Leu-Gly-OC2H5 for both). The hydrolysis of the substrate increases
the absorbance at 412 for both MMP2 and MMP9 respectively. A plot of the increased
absorbance with time was generated where the slope of the curve is directly related to
the enzyme activity. Similar curves were generated with standard solutions containing
known concentrations of purified MMP2 and MMP9 and slopes were calculated. Using
these slope values, the activity of MMP2 and MMP9 in the wound fluid was then
estimated.
5.2.2 Growth Factor Degradation Studies at Biological Protease Levels
To determine if the elevated MMP2 and MMP9 levels found in the human chronic
wound fluid were contributing to the PDGF degradation seen previously in degradation
studies, biologically chronic levels of MMP2 and MMP9 (162mU/ul for MMP2 and 143
mU/ul for MMP920) were incubated at 370C with PDGF-ELP (1mg/ml in PBS, total volume
50 μl) and, at specified time points, 6ul of the samples was collected. The collected
samples were then tested via western blot using an antibody specific to PDGF (Peprotech
500-P45, 0.2ug/ml dilution used for blotting) to follow the degradation of PDGF over time.
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5.2.3 Synthesis of Expression Plasmids Containing Additional Protease Inhibitors
For the MMP2 and MMP9 inhibitory fusion proteins, genes encoding for the MMP2
inhibitory STX (CSCSDMTDKECLYFCMSEMS) the MMP9 inhibitory APP peptide
(ISYGNDALMP) 31 were individually cloned in frame with the gene encoding Elastin-LikePeptide (ELP,[(VPGVG)2-VPGLG-(VPGVG)2]10-DYKDDDDK) at the N-terminus within
the PUC19 plasmid. These new fusion DNA fragments (now coding either APP-ELP or
STX-ELP) were then excised using PflmI and BglI from the PUC19 vector and cloned into
a modified pET25B+ vector containing an Sfi1 site as described previously

29.

All gene

sequences were confirmed by sequencing after inserting them in the expression plasmid.
For the new HNE inhibitory fusion proteins, the gene encoding for the HNE
inhibitory SLPI (CSCSDMTDKECLYFCMSEMS) were cloned in frame with the gene
encoding Elastin-Like-Peptide (ELP,[(VPGVG)2-VPGLG-(VPGVG)2]10-DYKDDDDK) at
the N-terminus within the PUC19 plasmid. In addition to this molecule, two other fusion
proteins were developed. One protein contained five reiterations of the PMPD2 gene
cloned in frame with the gene encoding Elastin-Like-Peptide (ELP,[(VPGVG)2-VPGLG(VPGVG)2]10-DYKDDDDK) at the N-terminus within the PUC19 plasmid. The other
combination protein contained both the gene for PMPD2 and SLPI, with one gene on
either side of the ELP component. These new fusion DNA fragments (now coding either
SLPI-ELP, (PMPD2)5-ELP, or PMPD2-ELP-SLPI) were then excised using PflmI and BglI
from the PUC19 vector and cloned into a modified pET25B+ vector containing an Sfi1
site as described previously

29.

All gene sequences were confirmed by sequencing after

inserting them in the expression plasmid.
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5.2.4 Expression and Purification of Fusion Proteins
Following synthesis, all five of the fusion proteins, APP-ELP] , STX-ELP, SLPIELP, PMPD2-ELP-SLPI, and (PMPD2)5-ELP were expressed and purified as described
previously.
5.2.5 Confirmation of Protease Resistant Activity
Tests similar to the kinetic assay used to characterize the inhibitory behavior of
PMPD2 were utilized. Instead of HNE, samples with known MMP2 and MMP9 levels were
used as control, with additional sample shaving varying concentrations of APP-ELP or
STX-ELP, allowing for a calculations of percent inhibition between the control and
inhibited samples. An additional control of PMPD2-ELP was utilized for comparison as
well.
5.2.6 Growth Factor Degradation Studies with Nanoparticle Formulations
For assessing the activity of the nanoparticle formulations, a 1:2 by weight mixture
of PDGF-ELP and either APP-ELP or STX-ELP in PBS were created. MMP2 or MMP9
(162mU/ul and 134mU/ul respectively) was then added to these NPs (total volume= 50
μl) and mixture was incubated at 37 0C. At the specified times 6 μl of samples were
collected. Growth factor degradation was then assessed by western blots using
antibodies specific to the corresponding growth factor: PDGF (Peprotech 500-P45,
0.2ug/ml dilution used for blotting).
5.3 Results
5.3.1 Elevated Additional Protease Activity Found in Human Chronic Wound Fluid
We performed a substrate-based assay to determine whether MMP2 and MMP9
were present in the chronic wound fluid samples. We found that 8 out of 11 patients
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showed elevated MMP2 and/or MMP9 activity. One patient had MMP2 levels associated
with 50% probability of a wound being non-healing (600 μU/ μl) and 8 of the 11 patients
had MMP2 and/or MMP9 levels associated with 25% chance of a wound being nonhealing 20(Figure 6A).
5.3.2 Elevated MMP2 and MMP9 Levels Potently Degrade Growth Factor
When the growth factor was incubated with biologically chronic levels of either
MMP2 or MMP9, a clear trend of continuous and potent degradation was seen, with only
trace amounts of the growth factor remained after 48 hours(Figure 6B).
5.3.3 Creation of MMP2 and MMP9 Inhibiting Fusion Protein APP-ELP and STX-ELP,
and Additional HNE Inhibitors SLPI-ELP, (PMPD2)5-ELP, and PMPD2-ELP-SLPI
Our results indicate that for successful application of growth factor therapy in
chronic wounds with high protease levels, the growth factor needs to be protected from
protease-mediated degradation. This would extend to all proteases found active in the
wound fluid. To that end, we developed a fusion proteins comprising of an ELP and a
previously described potent MMP2 or MMP9 inhibiting peptide, APP and STX respectively
31.

We were successfully able to express both proteins in E-coli and purified them via ITC.

This same process was used to develop the additional HNE inhibiting fusion proteins,
SLPI-ELP, (PMPD2)5-ELP, and PMPD2-ELP-SLPI.
5.3.4 Nanoparticle Formulation Inhibitory Activity Confirmed
Following successful purification, the inhibitory properties of APP-ELP and STXELP towards MMP2 and MMP9 were assessed using a substrate based kinetic assay.
Indeed, both APP-ELP and STX-ELP both showed 100% protease inhibition at a
concentration of 2 mg/ml.
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Using the same methodology, the inhibitory properties of SLPI-ELP, (PMPD2)5ELP, and PMPD2-ELP-ELP towards HNE were assessed using a substrate based kinetic
assay , with the results compared against PMPD2-ELP. Two of the fusion proteins
showed inhibition of their respective protease.
At concentrations of 0.01mg/ml, PMPD2-ELP showed 100% inhibition, PMPD2ELP-SLPI both showed 95% inhibition, and SLPI-ELP showed 75% inhibition. (PMPD2)5ELP showed very low levels of inhibition (Figure 7A-7B).
5.3.5 Nanoparticle Formulation Protects Growth Factor from Protease Degradation
The fused ELP sequences allowed us to create heterogeneous nanoparticles
(NPs) comprising of both APP-ELP or STX-ELP, along with PDGF-ELP (Figure 4A).
These NPs protected PDGF from MMP2 and MMP9 mediated degradation in buffered
solutions containing MMP2 and MMP9 162mU/ul and 134mU/ul respectively, compared
to homogeneous NPs comprising of the growth factors alone (Figure 7C) .
5.4 Discussion
The next step was to understand why we were seeing unexpected degradation
from a subset of the patient chronic wound fluid samples. In most cases were saw
significant success improving growth factor preservation, but in a few cases there was
little improvement.
One group of these samples that did not show significant improvement is those
which presented with the highest levels of HNE, which suggested this HNE activity had
overwhelmed that of the PMPD2-ELP component. To address this issue, we sought to
develop different, stronger HNE inhibitory fusion proteins. To that end, the peptide SLPI
was utilized, along with the ELP, to successfully develop and purify an additional HNE
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inhibitor. In addition to this, two more novel fusion proteins were developed with multiple
inhibitory gene sites, PMPD2-ELP-SLPI and (PMPD2)5. While PMPD2-ELP-SLPI and
SLPI-ELP both matched the inhibitory ability of PMPD2-ELP at higher concentrations,
they did not surpass inhibitory activity of the original PMPD2-ELP protein at a
concentration of 0.01mg/ml. Indeed, the closest either of theses new proteins came to
PMPD2’s levels of inhibition was 95% inhibition, seen from the PMPD2-ELP-SLPI
combination protein, compared to the 100% inhibition seen from the original PMPD2-ELP
protein. (PMPD2)5-ELP specifically was found to have almost no inhibitory activity at
.01mg/ml. Overall, no improvements were seen between the single PMPD2-ELP protein
and its combination counterparts, suggesting that the only activity seen in these new
proteins was due to the original PMPD2-ELP component of either protein. This suggests
that there is no benefit to placing multiple HNE inhibitors in the same fusion protein,
despite the potential for synergy. One possible explanation for this is that there may be a
steric issue that prevents the binding of one domain following successful binding of
another domain. This issue could potentially be addressed by elongating the ELP
sequence to put enough space in between the domains to allow for binding on both sides
without interfering with either binding site. Additionally, concern should be taken to
determine if significant charges on the ends of the ELP could have an effect of the
conformation of the protein.
Another subset of those samples which showed little improvement were those
samples with the lowest levels of HNE. One possibility to explain this would be the
presence of additional proteases, as these proteases would not be inhibited by the same
peptide as HNE. There are several other common proteases naturally found in the human
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chronic wound environment that could be present and experiencing upregulation such as
MMPs. Kinetic assay results showed elevated levels of both MMP2 and MMP9 in eight
out of eleven samples with one sample having a MMP2 level correlated with a 50%
chance of a wound being chronic, and seven of the eleven samples having either MMP2
or MMP9 level associated with a 25% chance of a wound being non-healing20. Biologically
chronic levels of MMP2 and MMP9 both resulted in significant degradation of PDGF in
less than 48 hours. This suggests the unexpected degradation seen earlier in the samples
with low HNE levels may be due to additional upcycled proteases in the wound site. This
potent degradation led to the successful development and purification of MMP inhibitory
fusion proteins. The optimal peptides for this purpose would be small in size and maintain
their bioactivity when fused to the ELP component28-30. APP and STX both individually
filled these requirements well, with their short sequences preserving the bioactivity of both
the ELP and their own well known and documented bioactivity when combined into
individual fusion proteins43. Both App and STX showed similar inhibitory abilities to that
of HNE, with both showing 100% inhibition when tested via kinetic assay. This inhibitory
activity is similar to previous studies which tested the inhibitory abilities of just the
synthesized peptide, suggesting that the fusion with the ELP has little if any effect on
either APP’s or STX’s inhibitory ability43. This inhibitory bioactivity successfully translated
to improved growth factor preservation in degradation experiments, with significantly
more growth factor preserved. This suggests great potential for the use of MMP inhibitors
for chronic wound treatment, especially for those wounds that have elevated MMP2 or
MMP9 levels.
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Overall, the additional protease resistant nanoparticle formulations APP-ELP and
STX-ELP proved very effective at inhibiting MMP2 and MMP9 activity. This is promising
for treatment of complex chronic wounds as it allows for the possibility of personalized
chronic wound treatment dependent on the protease levels and distribution. While the
additional HNE inhibitory fusion proteins were not successful at surpassing the efficacy
of the original PMPD2-ELP fusion protein, there is potential that extension of the ELP or
balancing of charges could be beneficial to allow for improved inhibition for those chronic
wounds with extremely elevated protease activity. The balancing of charges could be
beneficial to allow for improved inhibition for those chronic wounds with extremely
elevated protease activity.

Figure 6: Additional Proteases Detected in Chronic Would Found Detrimental to be
Detrimental to Growth Factor. A) The wound fluid was tested for MMP activity using
substrate assays, with the results showing several samples presenting with biologically
chronic levels of either MMP2 or MMP9. (B) Concentrations of MMP2 and MMP9 similar
to those found in the chronic wounds20 were incubated with PDGF, with samples taken at
various time points, and visualized via western blot. Results showed dramatic degradation
of growth factor within 48 hours as shown in this example western blot.
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Figure 7: Bioactivity of Additional Protease Resistant Nanoparticle Formulations
Confirmed. (A) The inhibitory efficiency of the APP-ELP and STX ELP fusion proteins
were tested via substrate assay and found to block protease activity at a concentrations
2mg/ml. (B) The inhibitory efficiency of the additional HNE inhibitory fusion proteins were
then tested via substrate assay and while both SLPI-ELP and PMPD2-ELP-SLPI were
both found to block protease activity at concentrations as low as 0.01mg/ml, neither were
as effective as PMPD2-ELP, which showed 100% inhibition at a concentration of
0.01mg/ml. (C-D)Growth factor alone or heterogeneous NPs containing growth factor and
protease inhibitor, either APP-ELP or STX-ELP were incubated with MMP2 and MMP9 at
the indicated times. Growth factor degradation was visualized using western blots using
antibodies specific to the PDGF. Both APP-ELP and STX-ELP showed success in
extending the half-life of the growth factor to over 48 hours.
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Chapter 6: Conclusion6
Chronic wounds are an emerging epidemic, with exponential growth expected as
the global rates of obesity increase, and with them the rates of diabetic and venous ulcers,
the most commonly hospitalized chronic wounds. Current treatments have addressed
many ways to effect positive change in the chronic wound environment, such as by the
addition of growth factors. The addition of these growth factors, such as PDGF, has
shown limited success in the clinic compared to its potential. This is likely due to
environmental factors such as elevated protease levels, which we have seen to have a
devastating degradative effect. The reality seems to be that any treatment for chronic
wounds that involves the use of growth factors would additionally require a component to
address elevated protease levels in the wound site. The novel fusion protein was
developed to combine just such an element, the HNE inhibitory PMPD2, with the selfassembling ELP. The inhibitory protein, combined with a PDGF-ELP component,
assembles to create a heterogeneous nanoparticle that was shown to maintain HNE
inhibitory properties at very low concentrations. The protein also maintained its ease of
purification, a property due to the ELP component. This same nanoparticle was shown to
protect PDGF from degradation in controlled buffered solutions, as well as in the
biological environments of human chronic would fluid. This novel protective system
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extending the half-life of the growth factor from less than 2 hours to 24 hours, a great
achievement when it comes to allowing adequate time for the growth factor to achieve
appropriate cell signaling to aid in wound healing. This success translated to the protease
supplemented animal model, where we saw improved reepithelization, reduced
inflammation, and improved collagen deposition and distribution. This protective system
designed to protect PDGF from HNE degradation is highly customizable, with the ability
to substitute in any inhibitory component to address additional protease activity, such as
that of MMPs or proteinases. This is exemplified in the two additional novel fusion proteins
developed to protect growth factors from degradation due to MMP2 and MMP9. These
additional inhibitory components for the protective systems designed to protect PDGF
from MMP degradation, APP-ELP for MMP2 and STX-ELP for MMP9, were both
successfully purified and found to be effective at preserving PDGF from degradation of
their respective proteases.
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Chapter 7: Innovation7
The main innovative component of this work was the development of heterogenous
nanoparticles that place the protease inhibitory component in close proximity to the
growth factor. Current methods have generally focused on altering the amino acid
sequence of the growth factors to make mutants with altered protease cleavage site. Our
results indicate that the same protease inhibitor component can be used to protect
multiple growth factors, thus eradicating the need to produce mutants for each growth
factors. Indeed, we showed rapid degradation of growth factors due to elevated proteases
found and incubated in human chronic wound fluid collected from patients. These
developed nanoparticles were found to be effective at preserving the growth factor in
question. Additionally, these protective nanoparticular systems may result in the
translation of growth factor based wound healing therapies to clinics.
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Chapter 8: Key Findings8
•

Chronic wound fluid samples were found to have elevated protease levels found
to have a devastating degradative effect on growth factors, including PDGF,
VEGF, KGF, and EGF.

•

The developed protective heterogenous nanoparticular system consisting of ELP
fusion proteins were successful at preserving growth factors from proteasemediated degradation in high protease environments

•

Treatment with these nanoparticles resulted in improved collagen deposition,
reduced inflammation, and improved re-epithelization in a diabetic rodent model
augmented with proteases in order to simulate the conditions found in the collected
human chronic wound fluid.
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Appendix C: Abbreviations and Acronyms
PDGF-Platelet Derived Growth Factor
ELP-Elastin-Like-Peptide
GF-Growth Factor
HNE-Human Neutrophil Elastase
MMP-Matrix Metalloproteinases
NP-Nanoparticle
EGF-Epidermal Growth Factor
KGF-Keratinocyte Growth Factor
VEGF-Vascular Endothelial Growth Factor
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